Merck & Co. confirmed that it has paused discussions to acquire clinical-stage biotech Revolution Medicines after failing to agree on a valuation for a potential takeover. Sources indicate that the deal could have approached a $30 billion valuation, driven by Revolution’s lead compound daraxonrasib entering Phase 3 trials for pancreatic and non-small cell lung cancer. While Merck has not ruled out resuming negotiations, the decision reflects its discipline in deal sizing and overall focus on prioritizing high-value oncology assets within its R&D pipeline.

During the recent quarter, Cullen/Frost Bankers Inc. reduced its holdings in Merck by 7.0%, selling approximately 17,000 shares and lowering its stake to 225,581 shares valued at $18.93 million. In contrast, Charles Schwab Investment Management increased its position by 9.4%, adding 4.6 million shares to reach a total holding worth $4.26 billion, while new entrants DLD Asset Management and Norges Bank each established positions of roughly $2.89 billion and $2.86 billion respectively. Collectively, institutional investors now control over 76% of Merck’s outstanding shares.

In its most recent quarterly report, Merck delivered earnings per share of $1.94, missing consensus estimates by $0.14, and achieved a net margin of 29.6%. The company declared a quarterly dividend of $0.85 per share, up 5% from the prior payout, representing a $3.40 annualized distribution and a dividend yield of approximately 3.1%. Merck’s return on equity stands at 44.5%, supported by a current ratio of 1.66 and a debt-to-equity ratio of 0.77, underscoring its strong balance sheet and cash-flow generation.

Following the acquisition news and latest results, analysts have updated their outlook for Merck. BMO Capital Markets upgraded the stock to outperform, raising its price target from $82 to $130. Goldman Sachs increased its objective from $92 to $120 with a buy rating, while Scotiabank and Bank of America both lifted targets to $120 and maintained positive sector-outperform views. Wolfe Research moved Merck from peer perform to outperform, setting a target of $135. Collectively, these nine buy ratings, seven holds and two sells imply a consensus target of approximately $114, reflecting mixed sentiment on near-term growth versus long-term pipeline prospects.